Peptide Comparison
Immunoxel (Dzherelo)vsThymalin
Ukrainian botanical immunomodulator that supercharges tuberculosis treatment and restores immune function in HIV patients
Russian thymic peptide complex that rejuvenates immune function and supports healthy aging
At a Glance
Quick
comparison
Dose Range
Immunoxel (Dzherelo)
25–50 drops
Thymalin
5–10 mg
Frequency
Immunoxel (Dzherelo)
Multiple times daily
Thymalin
Once daily
Administration
Immunoxel (Dzherelo)
Oral (liquid drops)
Thymalin
Intramuscular injection
Cycle Length
Immunoxel (Dzherelo)
8-12 weeks
Thymalin
4-6 weeks
Onset Speed
Immunoxel (Dzherelo)
Moderate (1-2 weeks)
Thymalin
Moderate (1-2 weeks)
Evidence Level
Immunoxel (Dzherelo)
Moderate human trials (Phase 1-2)
Thymalin
Limited human trials
Efficacy
Benefit
ratings
TB Treatment Enhancement
Immune Restoration
Infection Prevention
Longevity Support
Disease Prevention
Technical Data
Compound
specifications
Immunoxel (Dzherelo)
Molecular Formula
N/A — multi-component herbal phytoconcentrate
Molecular Weight
N/A — complex botanical mixture of multiple plant compounds
Half-Life
Not precisely characterized; immunomodulatory effects develop over days to weeks of consistent dosing
Bioavailability
Good oral and sublingual bioavailability; sublingual lozenges shown equivalent to twice-daily oral liquid
CAS Number
Proprietary combination
Thymalin
Molecular Formula
Complex mixture; active dipeptide EW: C16H19N3O5
Molecular Weight
Polypeptide complex; components 250-1000 Da; active dipeptide EW ~321 Da
Half-Life
Not precisely characterized for complex; immune effects persist weeks post-administration
Bioavailability
High via intramuscular or subcutaneous injection
CAS Number
63958-90-7
Protocols
Dosing
tiers
Immunoxel (Dzherelo)
Thymalin
Applications
Best
suited for
Immunoxel (Dzherelo)
Tuberculosis Adjunct Treatment
Immunoxel's strongest evidence is as an add-on to standard TB drugs. A meta-analysis of 6 clinical trials found patients receiving Immunoxel were 3.19 times more likely to become sputum-negative compared to TB drugs alone. In one study, 84.1% of patients converted within 1 month versus only 19% on placebo.
HIV/TB Coinfection Immune Support
For patients battling both HIV and TB simultaneously, Immunoxel offers remarkable immune benefits. Clinical trials showed CD4+ T-cell counts increased by 71.2% in just 2 months, viral load decreased significantly, and opportunistic infections dropped from 12 episodes to just 3 compared to standard therapy alone.
Drug-Resistant Tuberculosis Support
Immunoxel has been studied in multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) patients where standard treatments often struggle. Its immune-boosting effects help the body fight TB even when the bacteria resist front-line drugs.
Thymalin
Aging Adults Seeking Immune Support
Thymalin is especially valuable for people over 55 whose thymus gland has naturally shrunk with age. By stimulating thymic function, it helps restore the immune training center that your body relies on to fight infections and stay healthy.
Longevity and Anti-Aging Protocols
Clinical studies tracking patients for 6-8 years showed Thymalin reduced mortality by 2.0-2.1-fold. Combined with Epitalon, the mortality reduction reached an impressive 4.1-fold, making this combination one of the most studied longevity peptide protocols.
Seasonal Illness Prevention
Research shows Thymalin cuts respiratory infection rates by 2.0-2.4-fold. A short 10-day course before cold and flu season can significantly boost your immune defenses for months afterward.
Safety Profile
Side
effects
Immunoxel (Dzherelo)
Common
- Well-tolerated in most patients
- Mild gastrointestinal discomfort
Uncommon
- Temporary taste changes
- Mild allergic skin reactions
- Mild headache
Serious
- Potential herb-drug interactions
Thymalin
Common
- No side effects in most patients
- Mild injection site reaction
Uncommon
- Transient low-grade fever
- Mild flu-like symptoms
- Temporary headache
Serious
- Severe allergic reaction
Research Status
Safety
& evidence
Immunoxel (Dzherelo)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Immunoxel has demonstrated a favorable safety profile across multiple clinical trials involving hundreds of patients with TB and TB/HIV coinfection. No serious adverse events have been reported in published studies. It is approved by Ukraine's Ministry of Health and has been used clinically since the late 1980s. Side effects are generally mild and gastrointestinal in nature.
Contraindications
- xKnown hypersensitivity to any of the plant ingredients in the formulation
- xPregnancy and breastfeeding (insufficient safety data)
- xSevere liver disease (contains alcohol-based extract)
- xUse as sole therapy for TB or HIV (must be combined with standard treatment)
Thymalin
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Thymalin has an excellent safety profile based on over 40 years of clinical use in Russia. Most patients experience zero side effects, and the peptide complex has been described as 'practically non-toxic' in research literature. It has been used safely in thousands of patients, including elderly populations over extended periods.
Contraindications
- xActive thymic tumors or malignancies
- xKnown hypersensitivity to animal-derived peptide products
- xPregnancy and breastfeeding (insufficient safety data)
- xSevere uncontrolled autoimmune disease without medical supervision
Decision Guide
Which is
right for you?
Choose Immunoxel (Dzherelo) if...
- Adjunct immunotherapy alongside tuberculosis treatment
- Immune restoration in HIV/TB coinfected patients
- Reducing opportunistic infection rates
- Supporting overall immune function during infectious disease treatment
Choose Thymalin if...
- Immune system restoration in aging adults
- Longevity and healthy aging support
- Reducing infection frequency and severity
- Multi-system health optimization